A detailed history of Banque Transatlantique Sa transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Banque Transatlantique Sa holds 200 shares of NTLA stock, worth $1,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Holding current value
$1,832
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$7.11 - $12.8 $1,422 - $2,560
200 New
200 $1,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $696M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Banque Transatlantique Sa Portfolio

Follow Banque Transatlantique Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Banque Transatlantique Sa, based on Form 13F filings with the SEC.

News

Stay updated on Banque Transatlantique Sa with notifications on news.